List view / Grid view
"The data presented today are very encouraging because they are…
4 October 2013 | By Novartis
"The data presented today are very encouraging because they are from studies that took place over four years..."
Novartis reaffirms continued innovation in transplant during anniversary year of…
4 September 2013 | By Novartis
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin...
Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for…
3 September 2013 | By Novartis
Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection[1]...
Novartis announced that the US FDA has granted breakthrough therapy…
20 August 2013 | By Novartis
Novartis announced that the US FDA has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM)...
Two new analyses from the Phase III TRANSFORMS study presented...
10 June 2013 | By Novartis
Two new analyses from the Phase III TRANSFORMS study presented...
Gilenya improved the key measures...
5 June 2013 | By Novartis
Gilenya improved the key measures...
"Lucentis was designed to save sight..."
8 May 2013 | By Novartis
"Lucentis was designed to save sight..."
New data presented...
21 March 2013 | By Novartis
New data presented...
New data will be presented...
13 March 2013 | By Novartis
New data will be presented...
Novartis announced the appointment of Timothy Wright...
9 November 2011 | By Novartis
Novartis announced the appointment of Timothy Wright...
